0001549595-23-000066.txt : 20231221 0001549595-23-000066.hdr.sgml : 20231221 20231221171953 ACCESSION NUMBER: 0001549595-23-000066 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231220 FILED AS OF DATE: 20231221 DATE AS OF CHANGE: 20231221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: van Houte Hans CENTRAL INDEX KEY: 0001817217 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 231506202 MAIL ADDRESS: STREET 1: C/O NURIX THERAPEUTICS, INC. STREET 2: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 4 1 wk-form4_1703197177.xml FORM 4 X0508 4 2023-12-20 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817217 van Houte Hans C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-12-20 4 S 0 3541 10.0031 D 71930 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $10.00 and the highest price at which shares were sold was $10.03. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. /s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte 2023-12-21